Insider Selling: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Sells 6,000 Shares of Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Christopher Haqq sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $14.35, for a total value of $86,100.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Christopher Haqq also recently made the following trade(s):

  • On Friday, September 15th, Christopher Haqq sold 6,000 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $15.30, for a total transaction of $91,800.00.
  • On Tuesday, August 15th, Christopher Haqq sold 7,604 shares of Atara Biotherapeutics stock. The shares were sold at an average price of $14.75, for a total transaction of $112,159.00.

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) opened at 13.55 on Friday. Atara Biotherapeutics, Inc. has a one year low of $11.80 and a one year high of $23.00. The company’s market capitalization is $414.07 million. The firm has a 50-day moving average of $15.47 and a 200-day moving average of $15.11.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.05). Analysts forecast that Atara Biotherapeutics, Inc. will post ($3.91) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Sells 6,000 Shares of Stock” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/27/atara-biotherapeutics-inc-atra-evp-christopher-haqq-sells-6000-shares-of-stock.html.

ATRA has been the topic of a number of analyst reports. Canaccord Genuity restated a “buy” rating and set a $47.00 price target on shares of Atara Biotherapeutics in a research report on Monday, September 11th. ValuEngine upgraded shares of Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research lowered shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Monday, August 28th. Jefferies Group LLC reiterated a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a research report on Thursday, August 31st. Finally, BidaskClub downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Three analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. Atara Biotherapeutics has a consensus rating of “Hold” and an average price target of $24.40.

Several hedge funds and other institutional investors have recently modified their holdings of ATRA. Wells Fargo & Company MN increased its position in Atara Biotherapeutics by 9.0% during the first quarter. Wells Fargo & Company MN now owns 58,252 shares of the biotechnology company’s stock worth $1,197,000 after purchasing an additional 4,791 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Atara Biotherapeutics by 5.3% during the first quarter. Bank of New York Mellon Corp now owns 120,097 shares of the biotechnology company’s stock worth $2,468,000 after buying an additional 6,069 shares during the period. Swiss National Bank boosted its stake in Atara Biotherapeutics by 9.6% during the first quarter. Swiss National Bank now owns 28,600 shares of the biotechnology company’s stock worth $588,000 after buying an additional 2,500 shares during the period. Parametric Portfolio Associates LLC boosted its stake in Atara Biotherapeutics by 62.6% during the first quarter. Parametric Portfolio Associates LLC now owns 25,389 shares of the biotechnology company’s stock worth $522,000 after buying an additional 9,774 shares during the period. Finally, American International Group Inc. boosted its stake in Atara Biotherapeutics by 7.1% during the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after buying an additional 948 shares during the period. Institutional investors and hedge funds own 82.74% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply